Ampion

BIOLOGICAL6 trials

Sponsors

Ampio Pharmaceuticals. Inc.

Conditions

COVID-19Covid19Severe Osteoarthritis of the Knee

Phase 1

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

CompletedNCT04456452

Ampio Pharmaceuticals. Inc.COVID-19

Start: 2020-07-27End: 2020-11-30Updated: 2021-01-13

Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

CompletedNCT04606784

Ampio Pharmaceuticals. Inc.Covid19

Start: 2020-10-28End: 2021-06-15Updated: 2022-03-21

A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

CompletedNCT04880161

Ampio Pharmaceuticals. Inc.Covid19

Start: 2021-07-26End: 2022-02-21Updated: 2023-09-21

Phase 2

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

TerminatedNCT04839965

Ampio Pharmaceuticals. Inc.COVID-19

Start: 2021-07-05End: 2022-04-04Updated: 2022-11-30

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

TerminatedNCT04868890

Ampio Pharmaceuticals. Inc.Covid19

Start: 2021-06-22End: 2022-04-13Updated: 2022-12-07

Phase 3

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

TerminatedNCT03988023

Ampio Pharmaceuticals. Inc.Severe Osteoarthritis of the Knee

Start: 2019-06-24End: 2021-07-13Updated: 2022-10-05

Related Papers

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection.

2021-11-142 citations